Abstract: Photocurable compositions that combine redox-active semiconducting organic polymers with photocurable organic molecules are provided. Upon exposure to radiation, the photocurable compositions form ion-permeable, electrically conductive crosslinked organic films that can be used as conducting channels in n-channel or p-channel organic electrochemical transistors, including vertical organic electrochemical transistors (vOECTs). The vOECTs can be incorporated in complementary electronic circuits.

Abstract: The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

Abstract: The present application relates to the fields of tumor treatment and molecular immunology, and specifically, to an anti-VEGFA/PD-1 bifunctional antibody, a pharmaceutical composition thereof and use thereof. Specifically, the anti-VEGFA/PD-1 bifunctional antibody comprises an antibody or antigen binding fragment thereof targeting VEGFA and an antibody or antigen binding fragment thereof targeting PD-1. The bifunctional antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 in an organism, and inhibit tumor-induced angiogenesis.

Abstract: The present invention belongs to the fields of tumor treatment and molecular immunology, and relates to a pharmaceutical composition comprising an anti-CTLA4-anti-PD-1 bispecific antibody and chiauranib. Specifically, the pharmaceutical composition comprises chiauranib or a pharmaceutically acceptable salt thereof or a crystalline form thereof, and at least one anti-CTLA4-anti-PD-1 bispecific antibody. The present invention also relates to use of the pharmaceutical composition.

Abstract: A roll-to-roll method of fabricating seamless microstructures is provided, including the steps of: (a) continuously forming a laminated structure comprising a photomask film superimposed on a substrate with a layer of photo-sensitive material therebetween, the photomask film including a pattern of light-transmissive regions and light-blocking regions; (b) illuminating the photomask film of laminated structure formed in step (a) such that light passes through the light-transmissive regions of the photomask film to cure portions of the photo-sensitive material exposed by the light-transmissive regions, while leaving the remaining portions of the photo-sensitive material covered by the light-blocking regions uncured; (c) delaminating the photomask film from the photo-sensitive material selectively cured in step (b); and (d) removing the uncured portions of the photo-sensitive material to form a layer of microstructures on the substrate from the cured portions of the photo-sensitive material.

Abstract: A cell modification system includes a separation module, a modification module, a culture module and a filter module. The separation module is configured to receive a blood sample, separate cells and plasma from the blood sample, and then separate target cells. The modification module is configured to receive the target cells and introduce a modification composite material into the target cells to convert the target cells into modified cells. The culture module is configured to receive and store the modified cells, and monitor a cell proliferation environment to facilitate the activation and proliferation of the modified cells. The filter module is configured to receive the modified cells after proliferating, determine whether the modified cells have been modified successfully, and output the cells that have been modified successfully as a therapeutic product. A cell modification device is also disclosed.

Abstract: The present invention belongs to the field of immunology, and relates to an anti-IL-1? antibody and pharmaceutical composition thereof and use of the same. Specifically, the present invention relates to an anti-IL-1? antibody or an antigen-binding fragment thereof, wherein a heavy chain variable region of the antibody comprises HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NO: 17-SEQ ID NO: 19, respectively; and a light chain variable region of the antibody comprises LCDR1-LCDR3 set forth in SEQ ID NO: 20-SEQ ID NO: 22, respectively. The antibody disclosed herein can effectively bind to human IL-1B, block the binding of IL-1B to a receptor IL-1R1 thereof, and inhibit the activation of downstream signaling pathways of IL-1B; having the potential of being used for preparing a medicament for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes in children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors.

Abstract: A fusion protein containing an anti-TIGIT antibody and TGF-?R, and a pharmaceutical composition and the use thereof. Specifically, disclosed is a fusion protein containing a first protein functional region for targeting TIGIT, and a second protein functional region having a TGF-? binding activity, wherein the first protein functional region is an anti-TIGIT antibody or an antigen-binding fragment thereof, and the heavy chain variable region of the anti-TIGIT antibody contains HCDR1-HCDR3 with amino acid sequences as respectively shown in SEQ ID NOs: 3-5, and the light chain variable region thereof contains LCDR1-LCDR3 with amino acid sequences as respectively shown in SEQ ID NOs: 8-10. The fusion protein can simultaneously inhibit TIGIT and reduce the TGF-? level, and has good potential for preparing an anti-tumor drug.

Abstract: The present invention relates to a pharmaceutical composition, which comprises an anti-CD73 (e.g., human CD73) antibody or an antigen-binding fragment thereof, and an anti-PD-1-anti-VEGFA bispecific antibody or an antigen-binding fragment thereof. Specifically, a heavy chain variable region of the anti-CD73 antibody comprises HCDR1-HCDR3 having amino acid sequences set forth in SEQ ID NOs: 15-17; and a light chain variable region of the antibody comprises LCDR1-LCDR3 having amino acid sequences set forth in SEQ ID NOs: 18-20.

Abstract: A large-area switchable electro-optic light modulator or display and method of manufacture are disclosed. The large-area light modulator comprises an array of individual light modulator units sandwiched between two larger light-transmissive substrates coated on their inner surfaces with light-transmissive electrode layers with electrical connections to each unit that do not compromise the transparency of the light modulator in an open state. The large-area display comprises an array of individual display units. A large-area light-transmissive substrate coated on its inner surface with a light-transmissive electrode layer is superposed on the individual display units with electrical connections to each unit that do not compromise the transparency of the display. The light modulator and the display can be readily manufactured using conventional equipment.

Abstract: The present invention relates to the field of tumor treatment and immunology biology. Provided are a pharmaceutical combination containing an anti-PD-1-anti-VEGFA bispecific antibody, and the use thereof. Specifically, the pharmaceutical combination comprises at least one bispecific antibody and at least one PARP inhibitor, wherein the bispecific antibody comprises a first protein functional region for targeting PD-1 and a second protein functional region for targeting VEGFA; and according to the EU numbering system, the heavy chain constant region of an immunoglobulin contained in the bispecific antibody is mutated at two sites, i.e. site 234 and site 235, and after mutation, the affinity constant of the bispecific antibody to Fc?RI, Fc?RIIa, Fc?RIIIa and/or C1q is reduced compared with the affinity constant of the bispecific antibody thereto before mutation.

Abstract: The present invention belongs to the field of biomedicine, and relates to an anti-LAG3 antibody, a pharmaceutical composition containing same, and the use thereof. Specifically, the present invention relates to an anti-LAG3 antibody or an antigen binding fragment thereof, wherein the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 9-11, respectively, and the light chain variable region comprises LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 12-14, respectively. The anti-LAG3 antibody of the present invention has superior affinity and specificity, and has good application prospects.

Abstract: An anti-PD1 (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and/or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoclonal antibody can bind to PD1 specifically, relieve immunosuppression of PD1 on an organism specifically and activate T lymphocytes.

Abstract: The present invention relates to the field of pharmaceuticals, particularly to an anti-TIGIT antibody, a pharmaceutical composition, and use thereof, and more particularly to use in combination with an anti-PD-1/anti-VEGFA antibody in preventing or treating a tumor. Specifically, the present invention relates to an anti-TIGIT antibody or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising HCDR1-HCDR3 having amino acid sequences set forth in SEQ ID NOs: 3-5, respectively; and the antibody comprises a light chain variable region comprising LCDR1-LCDR3 having amino acid sequences set forth in SEQ ID NOs: 8-10, respectively. The antibody of the present invention can effectively bind to TIGIT and has the potential for use in tumor prevention and treatment.

Abstract: Switchable light modulator suppresses aperture and array diffraction, reducing blurring of images viewed through films. The light modulator includes a first light-transmissive substrate, a first electrode on one side of the first light-transmissive substrate, a second light-transmissive substrate, a second electrode on one side of the second light-transmissive substrate, a light-transmissive polymeric structure between the first electrode and the second electrode, and an electro-optic medium contained in cells in the polymeric structure. The polymeric structure includes a base and a wall structure defining the cells. Each cell includes wells on the base. The wall structure includes pillar structures and linking wall elements connecting adjacent pillar structures. The pillar structures include distal surfaces parallel to the base arranged with the wells in a given pattern.

Abstract: The present application relates to the fields of tumor treatment and molecular immunology, and specifically, to an anti-VEGFA/PD-1 bifunctional antibody, a pharmaceutical composition thereof and use thereof. Specifically, the anti-VEGFA/PD-1 bifunctional antibody comprises an antibody or antigen binding fragment thereof targeting VEGFA and an antibody or antigen binding fragment thereof targeting PD-1. The bifunctional antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 in an organism, and inhibit tumor-induced angiogenesis.

Abstract: The present application provides a high-strength flame-retardant MXene/phosphorylated cellulose fibril composite film and a preparation method thereof, belonging to the technical field of polymer materials. Dispersing uniformly phosphorylated cellulose nanofibrils into aqueous solution, adding chitosan and MXene and mixing evenly, drying to obtain the composite film. The present application utilizes MXene and introduces chitosan to enhance the flame-retardant performance and thermal stability of phosphorylated cellulose nanofibrils, meanwhile, strengthen the interaction between MXene and phosphorylated cellulose nanofibrils, combining the nano-enhancement effect of MXene can improve the mechanical properties of composite film. The phosphorylated cellulose fibril composite film prepared by MXene and chitosan co-modified not only has excellent flame-retardant properties, but also improves its mechanical properties.

Abstract: Disclosed are a wiring harness and a head-mounted device with the same. The wiring harness includes: a signal line including a plurality of signal conductors, a grounding wire including a plurality of grounding conductors, and a power cable including a plurality of power conductors, the signal line, the grounding wire and the power cable being disposed in the same outer sheath, and being sequentially arranged in a first direction.

Abstract: This disclosure relates to a context enforcement system that efficiently and securely protects tenant context information that travels across microservices in a multi-tenant distributed cloud computing system and protects against data leaks that often occur in conventional microservice management systems. For example, the context enforcement system ensures secure external and internal communications and context isolation by providing various shared library functions to microservices of a multi-tenant distributed cloud computing system. Additionally, the shared library provided by the context enforcement system improves the efficiency of the multi-tenant distributed cloud computing system by allowing microservices to focus on target operations rather than also maintaining and performing additional redundant functions.